HER2 positivity is associated with phenotypic and biologic aggression, characterized by an increase in cellular proliferation, motility, invasiveness, metastasis, angiogenesis, decreased apoptosis, and chemotherapy resistance as compared to luminal A (ER+/PgR+, HER2-) breast cancer[3,4]. The gene discussed is PGR; the disease is breast cancer.